MétaCan
Menu
← Back to cohort
Record W1136861330

Regression of primary breast tumor and blockage of osteolytic skeletal metastasis by a non-RGD based integrin binding peptide (ATN-161) targeting α5β1 and αvβ3 in a xenograft model of breast cancer

2004· article· en· W1136861330 on OpenAlexaff
Parisa Khalili, M L Plunkett, Ivy Beck, Jason Arimura, Andrew P. Mazar, Shafaat A. Rabbani

Bibliographic record

VenueCancer Research · 2004
Typearticle
Languageen
FieldMedicine
TopicBone health and treatments
Canadian institutionsMcGill University
Fundersnot available
KeywordsMedicineMetastasisBreast cancerCancerPrimary tumorCancer researchMalignancyInternal medicinePathologyOncology
DOInot available

Abstract

fetched live from OpenAlex

Proc Amer Assoc Cancer Res, Volume 45, 2004 4001 Breast cancer is commonly associated with osteolytic skeletal metastasis which results in considerable morbidity and mortality. In the late stages of this malignancy, tumor cells become hormone insensitive and metastasize to several organs including skeleton. ATN-161 is a 5-mer capped peptide that binds to activated α5β1 and ανβ 3 and is currently completing a Phase I trial in patients with advanced solid cancer. In the current study, we have evaluated the ability of ATN-161 to block primary tumor growth and the development of skeletal metastases in a xenograft model of breast cancer. Human breast cancer cells MDA-231 (1 X 105) transfected with green fluorescent protein (MDA-231-GFP) were inoculated into the mammary fat pad of female Balb/c nu/nu mice. After staging of tumors to 50 mm3, animals were infused with vehicle alone or ATN-161 (1 mg/kg 3x/week) i.v. for 6 weeks. Tumor volume of control animals infused with vehicle alone continued to increase over time. In contrast, tumors in experimental animals receiving ATN-161 either regressed or grew significantly more slowly than tumors inbc ontrol animals. In other studies, mice were infused with vehicle alone or ATN-161 for 10 weeks after intracardiac (i.c.) inoculation of tumor cells. Animals were monitored weekly by Faxitron for the development of skeletal metastases. At the end of the study, control and experimental animals were euthanized and and the organs analyzed for the presence of microscopic tumor metastases. While fluorescent metastatic tumor cells were routinely seen in the lungs, liver and spleen of control animals, treatment with ATN-161 resulted in a significant decrease in the number of tumor metastases in these organs. Radiological analysis of long bones demonstrated that ATN-161 treatment completely blocked the development of osteolytic skeletal metastases in the femora and tibia of 3/10 animals and led to a significant decrease in the number and size of osteolytic lesions in 7/10 animals. Bone histomorphometric analysis showed a significant decrease in the total area of osteolysis and tumor/bone ratio in the ATN-161 treated mice. Collectively, these studies demonstrate that ATN-161 can inhibit the progression of primary breast cancer and the development of tumor metastases to soft tissues and skeleton. These studies provide rationale for the development of ATN-161 as an effective therapeutic strategy for patients with late stage breast cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0020.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.368
Teacher spread0.327 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2004
Admission routes1
Has abstractyes

Explore more

Same venueCancer Research→Same topicBone health and treatments→French-language works237,207→